| Intel, AMD decide to settle all disputes | 12-NOV-09 |
|
| The world's two largest computer chip makers, Intel Corporation and Advanced Micro Devices (AMD), today announced their decision to end all legal disputes and antitrust litigations between themselves. |
|
|
|
| Venus Remedies bags patent for Potentox in SA | 12-NOV-09 |
|
| Venus Remedies has bagged patent for Potentox drug from South African patent controller. This is the company’s third product patent in South Africa this year. Companies Intellectual Property Registration Office, South Africa, has granted the company patent of two more drugs – Sulbactomax and Tobracef. |
|
|
|
| Valuing Intellectual Property | 20-OCT-09 |
|
| A leading global IT solutions company needs to value software applications acquired as a part of a business combination for financial reporting purposes. A fully integrated healthcare company intended to transfer rights and ownership of certain intellectual property related to bio-generics to a group company at fair valuation. A large spirits company requires to value its product related intangibles / brand for the purpose of debt financing. |
|
|
|
| Ranbaxy wins US court ruling on Roche patent | 17-OCT-09 |
|
| Daiichi Sankyo-owned Ranbaxy Laboratories has won a decisive ruling from the District Court of New Jersey that its generic version of valganciclovir, prescribed for HIV/Aids patients and for organ transplantation-related infections, does not infringe the patent rights of Swiss drug maker Roche's anti-infection drug, Valcyte. |
|
|
|
| Ranbaxy hails US court ruling on Valcyte patent | 16-OCT-09 |
|
| Ranbaxy laboratories today welcomed a ruling by a US district court that said the company's generic version of anti-viral drug Valcyte did not infringe Swiss pharma firm Roche's patent. |
|
|
|
| Suven Life Sciences granted patents in 9 markets | 14-OCT-09 |
|
| Suven Life Sciences, a Hyderabad-based biopharmaceutical company specialising in central nervous system (CNS) diseases, on Wednesday said that its clinical candidate for Alzheimer’s disease has secured product patent in India, Mexico, South Africa, Singapore, New Zealand, Korea, Eurasia, Australia and Europe markets. |
|
|
|
| Latha Jishnu: The campaign against that pesky 3 (d) | 14-OCT-09 |
|
| For the Americans (and some Europeans) it’s “that pesky section”. And the US government is throwing its weight behind an industry campaign to discredit this section if not get it removed from India’s Patent Act. Yes, of course, it is Section 3(d) that is under attack from big pharma which has lost no opportunity in pointing out that this law will stifle the growth of India’s own drug companies and also choke off foreign investment in the sector. In recent weeks, this campaign has picked up in tempo both here and abroad. |
|
|
|
| Mashelkar clarifies on patent report conclusions | 13-OCT-09 |
|
| Nearly two months after Argentine patent expert Carlos M Correa complained about the misinterpretation of his observations to conclude an expert group report on Indian patent laws, the chairman of the Technical Expert Group (TEG), R A Mashelkar, clarified that the report’s conclusions were not based on Correa’s views, but on TEG’s own interpretations. |
|
|
|
| Bharat Biotech secures patent for Lysostaphin | 02-OCT-09 |
|
| Hyderabad-based vaccines and biotherapeutics manufacturer Bharat Biotech International said on Wednesday that its anti-staphylococcal molecule Lysostaphin had secured patent rights in US, Europe, China, Australia and other nations. |
|
|
|
| Bharat Biotech gets patent for Lysostaphin | 30-SEP-09 |
|
| Hyderabad-based vaccines and biotherapeutics manufacturer Bharat Biotech International announced on Wednesday that its anti-staphylococcal molecule Lysostaphin had secured patent rights in US, Europe, China, Australia and other nations. |
|
|
|
| Latha Jishnu: Recession and the global patent effect | 30-SEP-09 |
|
| What happens when the apex patents organisation brings an economist, sorry, a chief economist, on board? You get a report that links the impact of the economic crisis to patent filings and seeks to explain a complex pattern through a fixed prism. You also get a report with a snappier title even if its conclusions are not entirely convincing. |
|
|
|
| Wockhardt gets award for patents | 24-SEP-09 |
|
| Drug maker Wockhardt today said it has been chosen as the pharmaceutical company for the maximum number of patent filings and grants from India. |
|
|
|
| Sun, Caraco to file 30 marketing applications for generics | 17-SEP-09 |
|
| Sun Pharmaceutical Industries and its troubled US subsidiary, Caraco Pharmaceuticals, plan to together file 30 Abbreviated New Drug Applications with the US Food and Drug Administration (FDA) to market generic drugs, despite regulatory issues for the US company. |
|
|
|
| US patent lawsuit against Dr Reddy's | 16-SEP-09 |
|
| US-based drug discovery firm Albany Molecular Research, Inc (Amri) has filed two new patent infringement lawsuits in the US District Court in New Jersey against Dr. Reddy’s Laboratories Ltd., Dr. Reddy’s Laboratories, Inc. and Sandoz, Inc. |
|
|
|
|
|
|
Content Guide
